Dr. Felicia Cosman is a clinical scientist, osteoporosis specialist, Professor of Medicine at Columbia University and North American Co-Editor in Chief of Osteoporosis International since 2016. She received a BA from Cornell, MD from Stony Brook, and completed internship, residency and endocrinology fellowship at Columbia University College of Physicians and Surgeons. She received the ACE Distinction in Endocrinology Award in 2019 and the ASBMR Bartter Award for clinical research in September 2020. Dr. Cosman has had many grants from NIH, DOD, MS Society, and industry and has published over 180 peer-reviewed papers and over 50 book chapters. The main focus of her research has been in the use of anabolic medications and treatment sequencing. Dr. Cosman has investigated the effect of teriparatide on biochemical markers, bone density, central and peripheral CT, bone strength by finite element analysis, and cellular action using iliac crest bone biopsy. She also studied the effect of teriparatide on bone formation in the human femoral neck in patients undergoing hip arthroplasty and performed a series of studies investigating cyclic, combination and sequential regimens of teriparatide and antiresorptive agents. Dr. Cosman has also been a major clinical investigator on multiple studies evaluating the effects of sequential therapy using romosozumab and abaloparatide. She is well known for advocating early use of anabolic treatment in very high-risk patients, optimizing treatment sequences and longterm treatment strategies, and implementing therapeutic goals for osteoporosis management.